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tigated over the past several years.1-6 Leukocyte deple-
tion has been shown to prevent myocardial edema, to
decrease the incidence of ventricular arrhythmias, and
Leukocyte depletion during cardiopulmonary bypass(CPB) and its effect on reperfusion injury and post-
operative lung dysfunction have been thoroughly inves-
Background: The propensity for leukocytes to cause reperfusion injury in
patients undergoing heart surgery is widely accepted. Reperfusion injury
may result in myocardial damage and unfavorable operative outcome, espe-
cially in patients with severely reduced ejection fractions. This study was
performed to evaluate the impact of leukocyte filtration on the postoperative
course of patients undergoing coronary bypass surgery. 
Methods: Thirty-two patients with coronary artery disease and left ventricu-
lar ejection fraction less than 35% were included in this double-blind, ran-
domized study. Two serial leukocyte removal filters (Pall BC1B filter [Pall
Biomedical, Portsmouth, England], group F, 15 patients) or two dummy fil-
ters (group C, 17 patients) were connected to the blood cardioplegia line.
Leukocyte count, hemodynamic measurement, and transesophageal echocar-
diography were performed before and after cardiopulmonary bypass.
Cardiac-specific enzymes were analyzed from arterial blood during the first
72 hours and from coronary sinus blood 30 and 60 minutes after aortic
unclamping.
Results: Patient characteristics were similar in the two groups (ejection frac-
tion 20.9% ± 4.3% in group C and 21.1% ± 4.8% in group F; P = .773). No
early death or perioperative myocardial infarction occurred. Leukocyte
count, hemodynamic parameters, cardiac troponin T, cardiac troponin I, and
creatine kinase MB mass levels in arterial blood were similar in the two
groups. Group F showed lower release of cardiac troponin T from the coro-
nary sinus 30 minutes after unclamping of the aorta (group F, 0.263 ± 0.12
ng/mL; group C, 0.6 ± 0.32 ng/mL; P = .005). Lower doses of dopamine
were necessary after cardiopulmonary bypass (group F, 0.36 ± 0.11 mg · kg–1
· min–1; group C, 0.49 ± 0.14 mg · kg–1 · min–1; P = .003). A moderate
increase in ejection fraction was observed at 30 minutes in both groups
(group F, 30.3% ± 6.2%; group C, 28.0% ± 6.3%; P = .239) and a significant
increase at 60 minutes in group F (group F, 32.5% ± 6.0%; group C, 27.4%
± 7.5%; P = .012).
Conclusions: These results indicate that serial leukocyte filters connected to
the blood cardioplegia line decrease myocardial cell injury and may there-
fore help to improve outcome of patients with severely depressed ejection
fractions undergoing coronary artery bypass grafting.  (J Thorac Cardiovasc
Surg 2000;120:642-50)
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Surgical protocol. Patients were premedicated with fluni-
trazepam by mouth (1 mg for those weighing < 70 kg or 2 mg
for those weighing > 70 kg) the evening before the operation.
Before the operation, patients received their usual morning
dose of antianginal medication and 2 mg of flunitrazepam.
Total intravenous anesthesia with sufentanil citrate (250-500
µg), pancuronium bromide (12-16 mg), and propofol (500-
1000 mg) was used. The first dose of cefazolin (2 g) was
given intravenously for infection prophylaxis during intro-
duction of anesthesia and the second dose (1 g) was given
after completion of CPB. After endotracheal intubation,
patients received mechanical ventilation with an oxygen
(FIO2: 0.5) and air mixture. Radial artery and thermodilution
pulmonary artery catheters (7F True Size thermodilution
catheter; Baxter Healthcare Corp, Irvine, Calif) were placed
for hemodynamic measurements. CPB was administered
with the use of a hollow-fiber membrane oxygenator (Bard
HF 5701, Bard, Inc, Haverhill, Mass) with a venous car-
diotomy reservoir. A roller pump (Multiflow, Stöckert,
Munich, Germany) was used with a standard nonpulsatile
flow rate of 2.4 L · min–1 · m–2. A 40-µm heparin-coated arte-
rial filter (Bentley, Irvine, Calif) was placed within the arter-
ial line. Standard cannulation technique was used with can-
nulas placed in the ascending aorta and right atrium (2-stage
venous cannula). After systemic heparinization (500
units/kg), CPB was initiated. Additional heparin was added
during CPB to maintain the activated clotting time over 400
seconds. The left ventricle was vented via the aortic root. A
14F retrograde cannula (RC-014; Research Medical,
Midvale, Utah) was placed into the coronary sinus. Distal
anastomoses of the grafts were performed during aortic
crossclamping, and proximal anastomoses were made after
unclamping. Patients were weaned from CPB as usual. When
necessary, dopamine (Dopamin; Giulini, Hannover,
Germany) was given to maintain the arterial blood pressure
over 80 mm Hg. If additional cardiac support was necessary,
enoximone (Perfan I.V.; Myogen, Westminster, Colo) was
administered. The consumption of inotropic drugs after aor-
tic unclamping up to the end of the operation was expressed
in milligrams per kilogram per minute. After completion of
CPB, heparin was neutralized by administration of protamine
sulfate (1 mg/100 units of heparin) to achieve an activated
clotting time of ±10% of baseline value. 
A prime solution comprising 1600 mL of Ringer solution
(Braun Schiwa B. GmbH & Co KG, Glandorf, Germany),
100 mL of mannitol 20%, 100 mL of sodium bicarbonate
8.4%, and 5000 units of heparin was used. Acid-base balance
was managed according to the alpha-stat concept. Two mil-
lion units of aprotinin (Trasylol; Bayer AG, Leverkusen,
Germany) was added in the priming solution and an addi-
tional dose of 1 million units after initiation of rewarming.
For myocardial preservation, two cold blood cardioplegic
solutions (4°C; 1:4 ratio of blood to cardioplegic solution)
were administered at a rate of 250 mL · min–1 for 4 minutes.
The composition of the two solutions was as follows: solution
I contained sodium chloride, 1.006 g; sodium hydroxide,
0.290 g; citric acid in water, 0.690 g; potassium chloride,
2.631 g; and glucose, 16.832 g; solution II contained sodium
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to reduce free radical–mediated lung injury7 and car-
diac reperfusion injury in animal models. Neutrophil
granulocytes may cause myocardial stunning due to
production of oxygen-derived free radicals,8,9 which
may damage cell membranes, sarcoplasmic reticulum,
and different enzymes. Furthermore, granulocytes can
plug capillaries during ischemia; after their degranula-
tion, cell membranes may be damaged by different cell
enzymes.10-15 Temporary reduction of circulating acti-
vated neutrophils by leukocyte-depleting filters during
the early period of reperfusion after ischemia may
decrease release of free oxygen radicals and therefore
reduce endothelial injury (eg, endothelial adherence,
capillary plugging, no-reflow phenomenon).10,13
Several reports describe leukocyte depletion in
human beings. A broad spectrum of indications for
leukocyte depletion in cardiac surgery is reported, such
as myocardial ischemia,16,17 heart transplantation,18,19
depressed left ventricular function,20 left ventricular
hypertrophy,21 cyanotic heart disease, and different
elective cardiac procedures.22-25
This study was performed in patients undergoing
coronary artery bypass grafting (CABG) with severely
depressed left ventricular function. The blood cardio-
plegic solution and initial reperfusion blood volume
were depleted of leukocytes only. This management
combines the advantages of leukocyte depletion during
the initial period of CPB and ischemia and the early
period of reperfusion.26 On the other hand, the techni-
cal problems of filtration of the total arterial blood vol-
ume could be avoided. 
Methods
Patients. The study includes 32 male patients undergoing
CABG during a 5-month period. The inclusion criteria were
left ventricular ejection fraction (LVEF) less than 35%, age
younger than 75 years, and elective or urgent CABG. Patients
with anemia, immunodeficiency, leukocytopenia, or thrombo-
cytopenia and reoperations were excluded from the study. The
patients were divided into two groups: group C (15 control
patients, who did not receive leukocyte-depleted blood cardio-
plegic solution) and group F (17 patients, who did receive
leukocyte-depleted blood cardioplegic solution [Pall BC1B
filter; Pall Biomedical, Portsmouth, England]). In group C,
two “dummy filters” were placed within the cardioplegia line,
and in group F, two leukocyte removal filters were inserted.
The study design was randomized and double blind. The per-
fusionist incorporated two Pall BC1B leukocyte removal fil-
ters or two empty dummy filters within the blood cardioplegia
line according to the random list. Neither the surgeon nor the
anesthesiologist was informed of the type of leukocyte
removal filter. All operations were performed by one surgeon
and one anesthesiologist, who handled transesophageal
echocardiography and hemodynamic measurements.
chloride, 1.043 g; sodium hydroxide, 0.298 g; citric acid in
water, 0.723 g; potassium chloride, 0.909 g; and glucose,
17.45 g (BC-Card I and BC-Card II; Planer, Graz, Austria).
Solution I was used initially until cardiac arrest and solution
II thereafter. Repeated doses (50 mL · min–1) were given
every 20 minutes. Solution II was then infused as the final
cardioplegic solution (“hot shot,” ≥34.5°C) for 4 minutes
immediately before aortic unclamping. For the next 6 min-
utes, either leukocyte-depleted or non–leukocyte-depleted
blood (50 mL · min–1) was administered. All patients received
a combination of antegrade and retrograde infusion of car-
dioplegic solution. Fifty percent of the cardioplegic solution
was given antegradely and 50% retrogradely. A heat exchang-
er for blood cardioplegia (Eurosets Vision; HMT,
Fürstenfeldbrück, Germany) was incorporated in the cardio-
plegia line. Patients were not actively cooled, but their sys-
temic temperature was allowed to drop to 33°C ± 1°C.
Rewarming was started 10 minutes before release of the aor-
tic clamp. 
Sample collection. Blood samples were collected proximal
and distal to the filters 2 minutes after the first doses of car-
dioplegic solution were begun and 2 minutes after the termi-
nal dose of cardioplegic solution was started. For hematolog-
ic testing, blood samples were taken from the radial artery
before initiation of CPB, 30 minutes after aortic crossclamp-
ing, and 1, 30, and 60 minutes and 6, 12, 24, and 48 hours
after completion of CPB. Samples for cardiac troponin T
(cTnT), troponin I (cTnI), and creatine kinase MB (CK-MB)
mass were taken from the coronary sinus before initiation of
CPB, 30 minutes after aortic crossclamping, and 1, 30, and 60
minutes after completion of CPB. Samples for cTnT, cTnI
and CK-MB mass were taken from the radial artery before
initiation of CPB, 30 minutes after aortic crossclamping, and
1, 30, and 60 minutes and 6, 12, 24, 48, and 72 hours after
completion of CPB. 
Leukocyte count. Blood cell counts were immediately
determined with the use of a counter (K-1000; Sysmex
Corporation of America, Long Grove, Ill) and differential cell
counting for neutrophils in Nageotte chambers with a dilution
of 1:100.
Biochemical assays. Blood samples were taken for bio-
chemical assays after defined time intervals. The blood sam-
ples were centrifuged for 10 minutes at 2000g. The serum
was frozen in aliquots and stored at –80°C until subsequent
analysis. CTnT was measured by means of the Troponin T
STAT immunoassay Elecsys 2010 Analyser (Roche
Diagnostics GmbH, Mannheim, Germany). CTnI was quanti-
fied by means of the Axsym Troponin I System (Abbott,
Wiesbaden, Germany). CK activity (CK-NAC; Boehringer
Mannheim, Division of Roche), CK-MB activity (Boehringer
Mannheim, Division of Roche), and CK-MB mass (Sandwich
immunoassay test) were calculated. Analysis was done at one
laboratory and without knowledge of the patients’ outcomes.
Hemodynamic measurements. Heart rate, mean arterial
blood pressure, and pulmonary capillary wedge pressure
were measured. Cardiac output was measured with the ther-
modilution technique. Cardiac index, stroke index, and left
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ventricular stroke work index were measured before initiation
of CPB (I), 30 minutes after completion of CPB (II), 60 min-
utes after completion of CPB (III), and 12 hours after admis-
sion to the intensive care unit (IV). 
Echocardiography. Intraoperative transesophageal
echocardiography was performed with a Hewlett-Packard
Sonos 2500 system and a 3.7/5.0-MHz phased-array omni-
plane transducer (Hewlett-Packard Company, Andover,
Mass). Left ventricular ejection fraction (LVEF) was calcu-
lated as follows: (End-diastolic volume – End-systolic vol-
ume)/End-diastolic volume. Left ventricular end-diastolic
and end-systolic volumes were estimated by acoustic quan-
tification (echocardiographic automatic border detection) in
the transverse 4-chamber view by means of the method of
discs (according to Simpson´s rule).
These echocardiographic data were measured before initi-
ation of CPB (I) and 30 minutes (II) and 60 minutes after
completion of CPB (III). 
Data analysis. Patients were randomized by means of a
computer-generated series of random numbers. The patients
were assigned to either leukocyte-depleted blood cardiople-
gia or non–leukocyte-depleted blood cardioplegia. The
results were reported as the mean ± the standard deviation of
the mean. The Mann-Whitney U test or Wilcoxon rank-sum
test for difference in medians was used for comparisons of
nominal data.
Ethics. All patients gave written informed consent, and the
study was performed according to the guidelines of the insti-
tutional ethical committee.
Results
Clinical results. Preoperative LVEF measured by
transthoracic echocardiography was 21.5% ± 4.2% in
group C and 21.1% ± 4.8% in group F (P = .773).
There were no significant differences regarding preop-
erative data and risk factors, surgical data, and patient
outcomes between group C and group F (Table I). All
patients survived and one patient with preoperative and
postoperative ventricular fibrillation received a defib-
rillator. Intensive care unit stay in group F was shorter,
but not significantly so (group C, 67.3 ± 102 hours;
group F, 40.6 ± 38.6 hours; P = .081). 
Leukocyte count. There was no effective leukocyte
depletion (neutrophil granulocytes) in group C, but
there was significant leukocyte depletion in group F.
Filtration rate was 96.0% during the first dose and
96.3% during terminal dose of cardioplegia (Fig 1).
Filtration of platelets was lower than 5% and no signif-
icant changes in systemic leukocyte count during the
first 72 hours was observed in either group. 
Measurement of cardiac enzymes. No significant
differences regarding systemic release of cTnT, cTnI,
and CK-MB mass during the first 72 hours was
observed in either group. In group C the peak value of
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Table I.  Patients’ characteristics, risk factors, and surgical data
Group C (n = 15) Group F (n = 17)
No.* % No.* % P value
Patient characteristics
Male/female 15/0 17/0
Age (y) 64.6 ± 8.0 63.6 ± 7.7 .793
BSA (m2) 1.95 ± 0.17 1.90 ± 0.15 .498
Weight (kg) 82.1 ± 10.4 78.1 ± 10.4 .326
EF (%) 20.9 ± 4.3 21.1 ± 4.8 .773
Previous MI 10/15 66.7 11/17 64.7
LVEDP (mm Hg) 26.1 ± 7.1 26.0 ± 9.1 .693
Risk factors
Smoking 5/15 33 7/17 41.2
Hypertension 8/15 55.3 7/17 41.2
Hyperlipidemia 5/15 33 6/17 35.3
Diabetes 4/15 26.7 7/17 41.2
COLD 5/15 33 3/17 17.7
Renal insufficiency 2/15 13.3 3/17 17.7
Carotid disease 1/15 6.7 3/17 17.7
Peripheral vascular disease 4/15 26.7 5/17 29.4
Surgical data
Operation time (min) 224.9 ± 30.3 221.1 ± 39.8 .895
CPB time (min) 116.8 ± 19.0 110.9 ± 23.7 .678
Crossclamp time (min) 72.1 ± 15.1 77.1 ± 22.4 .305
Distal anastomosis 4.1 ± 1.2 4.0 ± 1.1 .910
Blood loss (mL/24 h) 390 ± 180 410 ± 220 .823
Intubation time (min) 341 ± 117 377 ± 189 .895
ICU stay (h) 67.3 ± 102 40.6 ± 38.6 .081
PO2/FIO2 1.0 (mm Hg) 333 ± 116 363.9 ± 92 .295
Death 0/15 0/17
MI 0/15 0/17
LCOS 0/15 0/17
IABP 0/15 0/17
Stroke 0/15 0/17
Infections 0/15 0/17
VF 1/15 6.7 0/17
The internal thoracic artery was used in 7 patients of group C and in 10 patients of group F. BSA, Body surface area; EF, left ventricular ejection fraction; MI, myocar-
dial infarction; LVEDP, left ventricular end-diastolic pressure; COLD, chronic obstructive lung disease; CPB time, duration of cardiopulmonary bypass; crossclamp
time, duration of aortic crossclamping; ICU, intensive care unit; PO2/FIO2 1.0, first oxygen partial pressure after CPB with FIO2 1.0; LCOS, low cardiac output syn-
drome; IABP, intra-aortic balloon pump assistance; VF, ventricular fibrillation.
*Unless otherwise indicated, the figures in these columns indicate the number of patients.
Fig 1. Leukocyte count proximal and distal to two Pall BC1B filters (group F) and proximal and distal to the
dummy filters (during first and terminal dose of blood cardioplegia).
cTnT (cTnI; CK-MB mass) was 4.91 ± 2.2 ng/mL
(165.7 ± 45.9 ng/mL; 9.05 ± 2.6 U/L) (P = .371; P =
.178; P = .562) and in group F, 3.52 ± 1.2 ng/mL (111.8
± 57.8 ng/mL; 8.1 ± 2.0 U/L) (Fig 2). Group F showed
significantly lower cTnT release from the coronary
sinus 30 minutes after aortic unclamping (group F,
0.263 ± 0.12 ng/mL; group C, 0.6 ± 0.32 ng/mL; P =
.005) and a moderate decrease after 60 minutes (group
F, 1.64 ± 1.35 ng/mL; group C, 2.09 ± 2.02 ng/mL; P
= .282) (Fig 3). 
Hemodynamic measurements. Hemodynamic vari-
ables (heart rate, mean arterial pressure, cardiac index,
stroke index, and left ventricular stroke work index)
were similar in the two groups before initiation of CPB.
These parameters were then evaluated 30 and 60 min-
utes after completion of CPB and 12 hours after admis-
sion to the intensive care unit. No significant changes
in hemodynamic parameters were seen in either group
(Table II). 
Requirement for dopamine and enoximone.
Significant lower doses of dopamine for weaning from
CPB were required in group F (group F, 0.36 ± 0.11 
mg · kg–1 · min–1; group C, 0.49 ± 0.14 mg · kg–1 ·
min–1; P = .003) (Fig 4). No additional enoximone was
given in group F (0/17), whereas 5 of 15 patients in
group C received additional doses of enoximone. All
patients (17/17) in group F had spontaneous sinus
rhythm after release of the aortic crossclamp, but 4 of
15 patients in group C required electrical defibrillation. 
Estimation of LVEF. The LVEF calculated by com-
puterized transesophageal echocardiography before
initiation of CPB (I) was similar in the two groups
(group F, 24.9% ± 4.5%; group C, 24.3% ± 4.1%; P =
.834). There was a moderate increase 30 minutes after
CPB (II) in both groups (group F, 30.3% ± 6.2%; group
C, 28.0% ± 6.3%; P = .239) and a significant increase
60 minutes after CPB (III) (group F, 32.5% ± 6.0%;
group C, 27.4% ± 7.5%; P = .024). The differences in
increase between LVEF I to LVEF III in group F
(24.9% ± 4.4% to 32.5% ± 5.9%; P = .0005) were sig-
nificantly higher than those in group C (24.3% ± 4.1%
to 27.4% ± 7.5%; P = .357) (Fig 5). 
Discussion
Most animal experiments using leukocyte depletion
show positive effects regarding left ventricular recov-
ery and lung function after ischemia and reperfusion.
Some controversies exist concerning indication, the
best time frame, and the best method for leukocyte
depletion. Different filtration methods have been
described in the literature, such as filtration of total
arterial or venous blood, filtration during the controlled
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Fig 2.  Measurement of cardiac enzymes (cTnT, cTnI, CK
mass) preoperatively and during the first 72 hours after the
operation. *Peak level; cTnT, cardiac troponin T, P = .371;
cTnI, cardiac troponin I, P = .178; CK mass, creatinine
mass, P = .562; 1 to 11, time points 1 to 11 (see “Sample
collection” in the “Methods” section).
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reperfusion period, filtration of the blood cardioplegic
solution, and filtration of blood components of CPB.
Despite laboratory evidence of leukocyte involvement
in reperfusion injury, most clinical trials do not show
any hemodynamic effect of leukocyte filtration. Data
from Pala and colleagues20 showed that leukocyte
depletion failed to be effective in patients with a normal
ejection fraction. Mihaljevic and colleagues24 stated
that leukocyte depletion of total arterial blood did not
improve postoperative lung function. However, other
studies demonstrate a beneficial outcome after leuko-
cyte filtration. De Vecchi and associates16 found that
leukocyte depletion improved the surgical results in
patients with moderate or severe left ventricular dys-
function. Cardiac index showed a trend to greater
improvement in the group with leukocyte depletion.
Baksaas and coworkers22 demonstrated that leukocyte
depletion during the reperfusion period reduced the
number of circulating leukocytes in patients undergo-
ing elective CABG. However, no effect was seen for
myeloperoxidase release, complement activation, or
interleukin 6 and interleukin 8 release. Suzuki and
coworkers25 found that leukocyte depletion of blood
cardioplegic solutions significantly decreased the
release of CK-MB and cTnT. 
These results are consistent with our observations. We
found a significant decrease of cTnT levels in coronary
sinus blood 30 minutes after unclamping the aorta when
using leukocyte filters. Only a moderate decrease of
cTnT levels in coronary sinus blood could be seen after
60 minutes. When looking at the peak levels of cTnT,
cTnI, and CK-MB mass in the systemic circulation dur-
ing the first 72 hours, we saw no significant differences
between the groups. Sawa and associates17,21 demon-
strated a better outcome in patients with acute myocar-
dial ischemia or left ventricular hypertrophy treated with
Fig 3. Troponin T (cTnT) release from coronary sinus 30 and 60 minutes after unclamping of the aorta. 
Table II.  Hemodynamic measurements
I P value II P value III P value IV P value
LVSWI (gm · m–1 · m–2)
Group C 36.1 ± 9.3 24.9 ± 7.3 29.8 ± 5.5 29.3 ± 8.4
Group F 27.6 ± 6.7 .103 23.1 ± 4.5 .656 20.7 ± 6.7 .0139 26.5 ± 6.45 .876
PCWP (mm Hg)
Group C 13.0 ± 2.7 13.9 ± 5.2 10.9 ± 1.9 14.6 ± 4.4
Group F 13.4 ± 5.4 .921 11.8 ± 4.4 .299 12.0 ± 2.1 .256 9.50 ± 2.8 .065
MAP (mm Hg)
Group C 73.4 ± 11.5 64.6 ± 13.4 74.5 ± 11.0 79.9 ± 17.8
Group F 77.7 ± 14.0 .440 64.7 ± 9.20 .894 70.7 ± 12.9 .486 84.2 ± 13.5 .878
CI (L · min–1 · m–2)
Group C 2.26 ± 0.39 3.32 ± 0.75 3.15 ± 0.80 3.00 ± 0.66
Group F 2.18 ± 0.50 .634 3.02 ± 0.38 .351 2.37 ± 0.43 .055 2.25 ± 0.17 .057
I, Before cardiopulmonary bypass; II, 30 minutes after the end of cardiopulmonary bypass; III, 60 minutes after the end of cardiopulmonary bypass; IV, 12 hours after
admission to the intensive care unit; LVSWI, left ventricular stroke work index; PCWP, pulmonary capillary wedge pressure; MAP, mean arterial pressure; CI, car-
diac index. 
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leukocyte-depleted terminal blood cardioplegia; they
measured a lower release of malondialdehyde as a mark-
er of lipid peroxidation, lower release of CK-MB, sig-
nificantly lower postoperative inotropic support and, in
patients with left ventricular hypertrophy, lower myocyte
damage and endothelial cell damage of capillaries. In
patients with cardiogenic shock,17 the same group
observed a significantly lower requirement for dopamine
for weaning from CPB in patients treated with leuko-
cyte-depleted blood cardioplegic solutions, as observed
by our group. Mihaljevic and coworkers24 stated that the
use of a leukocyte-depleting filter in the arterial line
(Leuko-Guard-6; Pall Biomedical, Portsmouth,
England) during CPB did not reduce the number of cir-
culating leukocytes at any time during or after filtration
(flow 1.8 L · min–1 · m–2). Mair and coworkers27 could
not achieve effective leukocyte depletion using an arter-
ial line filter (LG6). However, Sawa and associates17,21
showed more than 95% leukocyte depletion in the coro-
nary circulation during terminal blood cardioplegia
reperfusion (Cellsorba-80P, Asahi Medical, Tokyo,
Japan) (300 mL · min–1 for 10 minutes). 
In our study we used two leukocyte filters during
blood cardioplegia and terminal reperfusion and
achieved more than 96% reduction of leukocytes in the
coronary circulation. This is consistent with the results
published by Suzuki and colleagues,25 who used the
same filter system (98.1% total leukocyte reduction
through the filter). Pala and coworkers20 tested leuko-
cyte-depleted blood cardioplegia in patients with an
LVEF lower than 35% or greater than 45%. They could
not observe an effect in patients with an LVEF greater
than 45%, but they found better myocardial protection
measured by glutathione redox ratio in patients with an
LVEF lower than 35%. We found a significant increase
of LVEF in the group with leukocyte depletion 60 min-
utes after CPB (P = .012). 
There were several hints that leukocyte depletion
with leukocyte filters effectively reduced myocardial
Fig 4. Requirement for dopamine for weaning from CPB.
Fig 5. Ejection fractions (EF) estimated by transesophageal
echocardiography in group F and group C. I, Before initiation
of CPB; II, 30 minutes after completion of CPB; III, 60 min-
utes after completion of CPB. 
cell damage in our patients. First, the level of cTnT was
reduced in group F. As we know, this enzyme is a sen-
sitive marker for myocardial tissue damage, which is
up-regulated shortly after ischemia. We assume that
cTnI, another specific marker for myocardial damage,
was not up-regulated significantly due to the small
number of patients enrolled in this study. Second, the
requirement for dopamine and enoximone was lower in
these patients. Obviously, these leukocyte filters even
have a positive hemodynamic effect on left ventricular
function. Transesophageal echocardiography objec-
tively confirmed these data. We are unable to explain
whether leukocyte filters may decrease early mortality
in patients with poor LVEF, since mortality was zero in
both groups. 
Study limitations
The two groups were identical concerning preopera-
tive infarction rate. However, viability testing by either
positron emission tomography or stress echocardiogra-
phy was not carried out. This, in theory, could show
differences regarding extent of viable myocardium that
could influence the results. Yet, since the groups were
properly randomized, we can assume that myocardial
viability of infarcted areas was nearly identical.
Endothelial markers were not investigated. However,
such markers could influence expression of free oxy-
gen radicals and therefore influence the results. 
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